Celsion's liver cancer therapy fails to meet late-stage trial goal Thu Jan 31, 2013 7:32am EST (Reuters) - Celsion Corp said a late-stage study of its experimental liver cancer treatment ThermoDox did not meet the main goal of increasing patients' survival without their cancer worsening. The study, named HEAT, was designed to show a 33 percent improvement in progression-free survival, Celsion said in a statement. Celsion CEO Michael Tardugno said the company is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox.